IQ Capital et al. invest £3.83m in Sirigen

The round was co-led by IQ Capital, NESTA and YFM Private Equity. Existing investors Seraphim Capital and Oxford Capital Partners also contributed. Ivan Griffin of Nesta and Max Bautin of IQ Capital were appointed to the company's board as investor directors.

The financing will be used to commercialise Sirigen's High Sensitivity Fluorescence technology, designed to significantly boost the performance of in vitro diagnostic tools.

Founded in 2003, Sirigen is a medical equipment company headquartered in Ringwood, Hampshire. Based on Nobel prize winning chemistry, Sirigen's technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications.

This technology is applicable to a diverse cross section of the biomedical industry including the drug discovery, life sciences and diagnostics sectors.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Grégoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com

 

 

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• YFM Group